Other Viral Hemorrhagic Fevers

Published on 25/03/2015 by admin

Filed under Pediatrics

Last modified 22/04/2025

Print this page

rate 1 star rate 2 star rate 3 star rate 4 star rate 5 star
Your rating: none, Average: 0 (0 votes)

This article have been viewed 1150 times

Chapter 263 Other Viral Hemorrhagic Fevers

Viral hemorrhagic fevers are a loosely defined group of clinical syndromes in which hemorrhagic manifestations are either common or especially notable in severe illness. Both the etiologic agents and clinical features of the syndromes differ, but disseminated intravascular coagulopathy may be a common pathogenetic feature.

Etiology

Six of the viral hemorrhagic fevers are caused by arthropod-borne viruses (arboviruses) (Table 263-1). Four are togaviruses of the family Flaviviridae: Kyasanur Forest disease, Omsk, dengue (Chapter 261), and yellow fever (Chapter 262) viruses. Three are of the family Bunyaviridae: Congo, Hantaan, and Rift Valley fever (RVF) viruses. Four are of the family Arenaviridae: Junin, Machupo, Guanarito, and Lassa viruses. Two are of the family Filoviridae: Ebola and Marburg viruses. The Filoviridae are enveloped, filamentous RNA viruses that are sometimes branched, unlike any other known virus.

Table 263-1 VIRAL HEMORRHAGE FEVERS (HFs)

MODE OF TRANSMISSION DISEASE VIRUS
Tick-borne Crimean-Congo HF* Congo
Kyasanur Forest disease Kyasanur Forest disease
Omsk HF Omsk
Mosquito-borne Dengue HF Dengue (four types)
Rift Valley fever Rift Valley fever
Yellow fever Yellow fever
Infected animals or materials to humans Argentine HF Junin
Bolivian HF Machupo
Lassa fever* Lassa
Marburg disease* Marburg
Ebola HF* Ebola
Hemorrhagic fever with renal syndrome Hantaan

* Patients may be contagious; nosocomial infections are common.

Chikungunya virus is associated infrequently with petechiae and epistaxis. Severe hemorrhagic manifestations have been reported in some cases.

Epidemiology and Clinical Manifestations

With some exceptions, the viruses causing viral hemorrhagic fevers are transmitted to humans via a nonhuman entity. The specific ecosystem required for viral survival determines the geographic distribution of disease. Although it is commonly thought that all viral hemorrhagic fevers are arthropod borne, 7 may be contracted from environmental contamination caused by animals or animal cells or from infected humans (see Table 263-1). Laboratory and hospital infections have occurred with many of these agents. Lassa fever and Argentine and Bolivian hemorrhagic fevers are reportedly milder in children than in adults.

Hemorrhagic Fever with Renal Syndrome

The endemic area of hemorrhage fever with renal syndrome (HFRS), also known as epidemic hemorrhagic fever and Korean hemorrhagic fever, includes Japan, Korea, far eastern Siberia, north and central China, European and Asian Russia, Scandinavia, Czechoslovakia, Romania, Bulgaria, Yugoslavia, and Greece. Although the incidence and severity of hemorrhagic manifestations and the mortality are lower in Europe than in northeastern Asia, the renal lesions are the same. Disease in Scandinavia, nephropathia epidemica, is caused by a different although antigenically related virus, Puumala virus, associated with the bank vole, Clethrionomys glareolus. Cases occur predominantly in the spring and summer. There appears to be no age factor in susceptibility, but because of occupational hazards, young adult men are most frequently attacked. Rodent plagues and evidence of rodent infestation have accompanied endemic and epidemic occurrences. Hantaan virus has been detected in lung tissue and excreta of Apodemus agrarius coreae. Antigenically related agents have been detected in laboratory rats and in urban rat populations around the world, including Prospect Hill virus in the wild rodent Microtus pennsylvanicus in North America and Sin Nombre virus in the deer mouse in the southern and southwestern USA; these viruses are causes of hantavirus pulmonary syndrome (Chapter 265). Rodent-to-rodent and rodent-to-human transmission presumably occurs via the respiratory route.

Clinical Manifestations

Dengue hemorrhagic fever (Chapter 261) and yellow fever (Chapter 262) cause similar syndromes in children in endemic areas.

Rift Valley Fever

Most Rift Valley fever infections have occurred in adults with signs and symptoms resembling those of dengue fever (Chapter 261). Onset is acute, with fever, headache, prostration, myalgia, anorexia, nausea, vomiting, conjunctivitis, and lymphadenopathy. The fever lasts 3-6 days and is often biphasic. Convalescence is often prolonged. In the 1977-1978 outbreak many patients died after showing signs that included purpura, epistaxis, hematemesis, and melena. RVF affects the uvea and posterior chorioretina; macular scarring, vascular occlusion, and optic atrophy occur, resulting in permanent visual loss in a high proportion of patients with mild to severe RVF. At autopsy in one report, extensive eosinophilic degeneration of the parenchymal cells of the liver were observed.

Argentine, Venezuelan, and Bolivian Hemorrhagic Fevers and Lassa Fever

The incubation period in Argentine, Venezuelan, and Bolivian hemorrhagic fevers and Lassa fever is commonly 7-14 days; the acute illness lasts for 2-4 wk. Clinical illnesses range from undifferentiated fever to the characteristic severe illness. Lassa fever is most often clinically severe in white persons. Onset is usually gradual, with increasing fever, headache, diffuse myalgia, and anorexia (Table 263-2). During the 1st wk, signs frequently include a sore throat, dysphagia, cough, oropharyngeal ulcers, nausea, vomiting, diarrhea, and pains in the chest and abdomen. Pleuritic chest pain may persist for 2-3 wk. In Argentine and Bolivian hemorrhagic fevers, and less frequently in Lassa fever, a petechial enanthem appears on the soft palate 3-5 days after onset and at about the same time on the trunk. The tourniquet test result may be positive. The clinical course of Venezuelan hemorrhagic fever has not been well described.

Table 263-2 CLINICAL STAGES OF LASSA FEVER

STAGE SYMPTOMS
1 (days 1-3) General weakness and malaise. High fever, >39°C, constant with peaks of 40-41°C
2 (days 4-7) Sore throat (with white exudative patches) very common; headache; back, chest, side, or abdominal pain; conjunctivitis; nausea and vomiting; diarrhea; productive cough; proteinuria; low blood pressure (systolic <100 mm Hg); anemia
3 (after 7 days) Facial edema; convulsions; mucosal bleeding (mouth, nose, eyes); internal bleeding; confusion or disorientation
4 (after 14 days) Coma and death

From Richmond JK, Baglole DJ: Lassa fever: epidemiology, clinical features, and social consequences, Br Med J 327: 1271–1275, 2003.

In 35-50% of all patients, these diseases may become severe, with persistent high temperature, increasing toxicity, swelling of the face or neck, microscopic hematuria, and frank hemorrhages from the stomach, intestines, nose, gums, and uterus. A syndrome of hypovolemic shock is accompanied by pleural effusion and renal failure. Respiratory distress resulting from airway obstruction, pleural effusion, or congestive heart failure may occur. A total of 10-20% of patients experience late neurologic involvement, characterized by intention tremor of the tongue and associated speech abnormalities. In severe cases, there may be intention tremors of the extremities, seizures, and delirium. The cerebrospinal fluid is normal. In Lassa fever, nerve deafness occurs in early convalescence in 25% of cases. Prolonged convalescence is accompanied by alopecia and, in Argentine and Bolivian hemorrhagic fevers, by signs of autonomic nervous system lability, such as postural hypotension, spontaneous flushing or blanching of the skin, and intermittent diaphoresis.

Laboratory studies reveal marked leukopenia, mild to moderate thrombocytopenia, proteinuria, and, in Argentine hemorrhagic fever, moderate abnormalities in blood clotting, decreased fibrinogen, increased fibrinogen split products, and elevated serum transaminases. There is focal, often extensive eosinophilic necrosis of liver parenchyma, focal interstitial pneumonitis, focal necrosis of the distal and collecting tubules, and partial replacement of splenic follicles by amorphous eosinophilic material. Usually bleeding occurs by diapedesis with little inflammatory reaction. The mortality rate is 10-40%.

Diagnosis

Diagnosis of these viral hemorrhagic fevers depends on a high index of suspicion in endemic areas. In nonendemic areas, histories of recent travel, recent laboratory exposure, or exposure to an earlier case should evoke suspicion of a viral hemorrhagic fever.

In all viral hemorrhagic fevers, the viral agent circulates in the blood at least transiently during the early febrile stage. Togaviruses and bunyaviruses can be recovered from acute-phase serum samples by inoculation into tissue culture or living mosquitoes. Argentine, Bolivian, and Venezuelan hemorrhagic fever viruses can be isolated from acute-phase blood or throat washings by intracerebral inoculation into guinea pigs, infant hamsters, or infant mice. Lassa virus may be isolated from acute-phase blood or throat washings by inoculation into tissue cultures. For Marburg disease and Ebola hemorrhagic fever, acute-phase throat washings, blood, and urine may be inoculated into tissue culture, guinea pigs, or monkeys. The viruses are readily identified on electron microscopy, with a filamentous structure differentiating them from all other known agents. Specific complement-fixing and immunofluorescent antibodies appear during convalescence. The virus of HFRS is recovered from acute-phase serum or urine by inoculation into tissue culture. A variety of antibody tests using viral subunits is becoming available. Serologic diagnosis depends on demonstration of seroconversion or a fourfold or greater increase in immunoglobulin G antibody titer in acute and convalescent serum specimens collected 3-4 wk apart. Viral RNA may also be detected in blood or tissues with use of reverse transcriptase polymerase chain reaction analysis.

Handling blood and other biologic specimens is hazardous and must be performed by specially trained personnel. Blood and autopsy specimens should be placed in tightly sealed metal containers, wrapped in absorbent material inside a sealed plastic bag, and shipped on dry ice to laboratories with biocontainment safety level 4 facilities. Even routine hematologic and biochemical tests should be done with extreme caution.

Prevention

A live-attenuated vaccine (Candid-I) for Argentine hemorrhagic fever (Junin virus) is highly efficacious. A form of inactivated mouse brain vaccine is reported to be effective in preventing Omsk hemorrhagic fever. Inactivated RVF vaccines are widely used to protect domestic animals and laboratory workers. HFRS inactivated vaccine is licensed in Korea, and killed and live-attenuated vaccines are widely used in China. A vaccinia-vector glycoprotein vaccine provides protection against Lassa fever in monkeys. A single dose of a recombinant vesicular stomatitis virus vaccine containing surface glycoproteins from Ebola and Marburg viruses is effective in preventing virus hemorrhagic fevers due to several strains of filovirus in a monkey model.

Prevention of mosquito-borne and tick-borne infections includes use of repellents, wearing of tight-fitting clothing that fully covers the extremities, and careful examination of the skin after exposure with removal of any vectors found. Diseases transmitted from a rodent-infected environment can be prevented through methods of rodent control; elimination of refuse and breeding sites is particularly successful in urban and suburban areas.

Crimean-Congo hemorrhagic fever, Lassa fever, Marburg disease, and Ebola hemorrhagic fever may be transmitted in hospital settings. Patients should be isolated until they are virus-free or for 3 wk after illness. Patients’ urine, sputum, blood, clothing, and bedding should be disinfected. Disposable syringes and needles should be used. Prompt and strict enforcement of barrier nursing may be lifesaving. The mortality rate among medical workers contracting these diseases is 50%. A few entirely asymptomatic Ebola infections result in strong antibody production.

Bibliography

Al-Hazmi A, Al-Rajhi AA, Abboud EG, et al. Ocular complications of Rift Valley fever outbreak in Saudi Arabia. Ophthalmology. 2005;112:313-318.

Centers for Disease Control and Prevention. Update: management of patients with suspected viral hemorrhagic fever. MMWR Morb Mortal Wkly Rep. 1995;44:475-479.

Centers for Disease Control and Prevention. Update: outbreak of Rift Valley fever—Saudi Arabia, August-November 2000. MMWR Morb Mortal Wkly Rep. 2000;49:982-985.

Geisbert TW, Hensley LE, Jahrling PB, et al. Treatment of Ebola virus infection with a recombinant inhibitor of factor VII a tissue factor: a study in rhesus monkeys. Lancet. 2003;362:1953-1958.

Geisbert TW, Geisbert JB, Leung A, et al. Single injection vaccine protects nonhuman primates against Marburg virus and three species of Ebola virus. J Virol. 2009;83:7296-7304.

Huggins JW, Hsiang CM, Cosgriff TM, et al. Prospective, double-blind, concurrent, placebo-controlled trial of intravenous ribavirin therapy of hemorrhagic fever with renal syndrome. J Infect Dis. 1991;164:1119-1127.

Leroy EM, Baize S, Volchkov VE, et al. Human asymptomatic Ebola infection and strong inflammatory response. Lancet. 2000;355:2210-2215.

Leroy EM, Telfer P, Kumulungui B, et al. A serological survey of Ebola virus infection in central African nonhuman primates. J Infect Dis. 2004;190:1895-1899.

Leroy EM, Kumulungui B, Pourrut X, et al. Fruit bats as reservoirs of Ebola virus. Nature. 2005;438:575-576.

McCormick JB, King IJ, Webb PA, et al. Lassa fever: effective therapy with ribavirin. N Engl J Med. 1986;314:20-26.

McCormick JB, King IJ, Webb PA, et al. A case-control study of the clinical diagnosis and course of Lassa fever. J Infect Dis. 1987;155:445-455.

2009 Outbreak news: Ebola Reston in pigs and humans, Philippines. Weekly Epid Record. 2009;7:49-50.

Peters CJ. Marburg and Ebola—arming ourselves against the deadly filoviruses. N Engl J Med. 2005;352:2571-2574.

Pourrut X, Delicat A, Rollin PE, et al. Spatial and temporal patterns of Zaire Ebolavirus antibody prevalence in the possible reservoir bat species. J Infect Dis. 2007;196:S176-S183.

Richmond JK, Baglole DJ. Lassa fever: epidemiology, clinical features, and social consequences. Br Med J. 2003;327:1271-1275.

Smego RAJr, Sarwari AR, Siddiqui AR. Crimean-Congo hemorrhagic fever: prevention and control limitations in a resource-poor country. Clin Infect Dis. 2004;38:1731-1735.

Towner JS, Pourrut X, Albarino CG, et al. Marburg virus infection detected in a common African bat. PLoS ONE. 2007;22:e764.

Towner JS, Rollin PD, Bausch DG, et al. Rapid diagnosis of Ebola hemorrhagic fever by reverse transcription-PCR in an outbreak setting and assessment of patient viral load as a predictor of outcome. J Virol. 2004;78:4330-4341.